Soft Solutions to exhibit at NRF’s 2008 show
NEW YORK Soft Solutions will exhibit its products at the 97th annual National Retail Foundation’s 2008 Retail’s Big Show, taking place next week at New York City’s Jacob Javits Center. The company is a provider of web-based retail merchandise management and support software to such companies as CVS and Carrefour.
Soft Solutions will display some of its applications during the show with emphasis on its latest products: ibs Analytics, Retail Operations Suite, Retail Master Data Management Suite and Embedded Service Oriented Architecture – mobile technology.
The ibs Analytics product provides merchandising increases the forecast accuracy for seasonal and regular items while taking into account product and product range complexities.
The ibs Store provides retailers a complete and centralized solution to meet all their store needs including increased margins, optimized POS profitability, controlled stocks and inventory, enhanced efficiency and improved customer support.
The embedded mobile technology incorporating a Service Oriented Architecture offers added flexibility and increased productivity in store operations and merchandising, offering retailers “anytime access” to critical data for running their businesseses.
The ibs Referential software manages master data from a company. The company will be present at the show on January 14–15.
Taro settles patent suit, launches generic Trileptal
HAWTHORNE Taro announced Wednesday that it has settled a patent lawsuit with Novartis and will launch oxcarbazepine tablets, the generic version of Novartis’ Trileptal. Oxcarbazepine tablets are indicated to treat seizures.
The litigation with Novartis centered on Taro’s Paragraph IV certification challenging Novartis’ patent protection on Trileptal. On Nov. 15, 2007, Taro received Food and Drug Administration approval for its abbreviated new drug application for oxcarbazepine tablets in 150 mg, 300 mg and 600 mg strengths, but the company waited to launch the drug until the lawsuit was settled.
According to Taro, Trileptal currently has annual U.S. sales of approximately $700 million.
Sciele to launch six medications in 2008
ATLANTA In addition to Sciele’s announcement last week, reported in Drug Store News, that it will launch its new Sular formulation during the first quarter of 2008, the company also announced plans to launch five other drugs this year:
- two new dosages of fenofibrate for the treatment of mixed dyslipidemia
- Prandin for Type 2 diabetes
- PrandiMet for Type 2 diabetes (pending FDA approval)
- a head lice asphyxiation product (pending FDA approval)
- a women’s health product
Sciele reaffirmed its full-year guidance at the JPMorgan 26th Annual Health Care Conference yesterday. As previously announced, full-year 2007 revenue is expected to range between $375 million and $385 million. The company expects full-year 2008 revenues to range from $440 million to $455 million.